Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: A model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914) [1]

Annals of Oncology

Volumn 17, Issue 5, 2006, Pages 875-

  Bonneterre, M E ^a   Bonneterre, J ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; FOLLOW UP; HEALTH CARE COST; HUMAN; LETTER; METASTASIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SURVIVAL TIME; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 33646176058     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj074     Document Type: Letter

References (3)

1. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: A model based cost-effectiveness analysis. Ann Oncol 2005; 16: 909-914.
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001; 344: 783-792.
3. Extra JM, Cognetti F, Maraninchi D et al. Trastuzumab (herceptin) plus taxotere vs taxotere alone as first line treatment of HER2-positive metastatic breast cancer (MBC): Results of a randomized multicentre trial. Eur J Cancer 2004; 2 (Suppl): 125 (Abstr 239).